

Date: July 21, 2020

- |   |   |
|---|---|
| <p>(1) BSE Ltd<br/>Listing Department<br/>Phiroze Jeejeebhoy Towers,<br/>Dalal Street,<br/>Mumbai - 400 001</p> | <p>(2) National Stock Exchange of India Ltd<br/>Listing Department<br/>Exchange Plaza, 5<sup>th</sup> floor,<br/>Plot no. C/1, G Block,<br/>Bandra Kurla Complex,<br/>Bandra (East), Mumbai - 400 051</p> |
|---|---|

**Scrip Code: 500087**

**Scrip Code: CIPLA EQ**

- (3) SOCIETE DE LA BOURSE DE LUXEMBOURG  
Societe Anonyme  
35A Boulevard Joseph II,  
L-1840 Luxembourg

**Sub- Disclosure under Regulation 30 of SEBI (listing Obligation and Disclosure Requirements), 2015**

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and as per the Certificate of Amalgamation issued by the Registrar of Companies, Sri Lanka dated July 21, 2020, we hereby notify that the Company's step-down wholly owned subsidiary, Cipla Pharma Lanka (Private) Limited, Sri Lanka (CPL) has amalgamated with Company's another step-down wholly owned subsidiary, Breathe Free Lanka (Private) Limited, Sri Lanka (BFL), with effect from May 01, 2020.

Upon amalgamation into BFL, CPL stands dissolved without winding up.

A detailed disclosure as required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are enclosed as Annexure- I.

Thank you,

For Cipla Limited

---

Rajendra Chopra  
Company Secretary

Enclosed:

1. Details as per the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as Annexure - I

### Annexure - I

Sr. No.	Particulars	Details
a)	Details and reasons for restructuring	<p><b>Companies involved in restructuring:</b></p> <ul style="list-style-type: none"> <li>• Cipla Pharma Lanka (Private) Limited, Sri Lanka (CPL)</li> <li>• Breathe Free Lanka (Private) Limited, Sri Lanka (BFL)</li> </ul> <p>Type of restructuring- Amalgamation of step-down subsidiaries.</p> <p><b>Reasons:</b> CPL was created as a (60:40) JV between Cipla (EU) Ltd ("Cipla EU"), wholly owned subsidiary of Cipla Limited, and the local distributor (JV partner). Basis the "Share Purchase Agreement" dated November 27, 2019, Cipla EU acquired JV partner's stake (400,000 LKR was paid for acquiring remaining 40% stake) in CPL, making CPL a wholly owned subsidiary. As a result, Cipla EU had two subsidiaries in Sri Lanka carrying on similar business.</p> <p>The amalgamation of CPL into BFL will consolidate the two entities into one and help in focused operational efforts, rationalization, standardization and simplification of business processes besides elimination of duplication which will result in operational synergies and reduction of costs.</p>
b)	quantitative and/ or qualitative effect of restructuring	All assets, liabilities, business operations and employees have been transferred to BFL
c)	details of benefit, if any, to the promoter/promoter group/group companies from such proposed restructuring;	Nil
d)	brief details of change in shareholding pattern (if any) of all entities.	<p>CPL will cease to exist and BFL will continue to remain wholly owned subsidiary.</p> <p>Effectively no change in shareholding pattern.</p>